| Issue |
Section |
Title |
File |
| Vol 18, No 1 (2016) |
Articles |
Systemic drug therapy of metastatic pancreatic cancer |
(Rus)
|
| Vol 21, No 3 (2019) |
Articles |
Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
(Rus)
|
| Vol 23, No 2 (2021) |
CLINICAL ONCOLOGY |
Pharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis |
(Rus)
|
| Vol 24, No 4 (2022) |
CLINICAL ONCOLOGY |
Place of durvalumab in the treatment of biliary tract cancer: A review |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study |
(Rus)
|
| Vol 26, No 2 (2024) |
Articles |
Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Comparison of efficacy and safety of regorafenib and anti-EGFR targeted therapy in metastatic colorectal cancer: A retrospective study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Comparative analysis of efficacy and safety of combined immunotherapy and immune targeted therapy in the first-line treatment of advanced renal cell carcinoma: a real-world study |
(Rus)
|
| Vol 27, No 1 (2025) |
Articles |
Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
The combination of lenvatinib and pembrolizumab in the treatment of patients with metastatic kidney cancer and factors of poor prognosis: experience of clinics in Moscow: A prospective observational study |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Role of enzyme replacement therapy for exocrine and nutritional insufficiency in patients with malignancies: A review |
(Rus)
|
| Vol 26, No 4 (2024) |
Articles |
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx |
(Rus)
|
